Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.690
-0.030 (-1.10%)
Dec 5, 2025, 4:00 PM EST - Market closed
Oramed Pharmaceuticals Revenue
Oramed Pharmaceuticals had revenue of $2.00M in the twelve months ending September 30, 2025.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
55.61
Revenue / Employee
$500,000
Employees
4
Market Cap
107.07M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ORMP News
- 18 days ago - Oramed Reports Fiscal Third Quarter 2025 Financial Results - PRNewsWire
- 18 days ago - ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS - PRNewsWire
- 6 weeks ago - Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives - PRNewsWire
- 7 months ago - Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - GlobeNewsWire
- 7 months ago - Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical - PRNewsWire
- 9 months ago - Oramed Pharmaceuticals Issues Letter to Shareholders - PRNewsWire
- 10 months ago - Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PRNewsWire
- 1 year ago - Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PRNewsWire